Available option
5mg / 1.2mL
Staff-prepared solution
Bear Biotech catalogue
Retatrutide
Triple GIP/GLP-1/glucagon receptor agonist research material
- GIP receptor
- GLP-1 receptor
- Glucagon receptor
Available presentations
Choose a strength and format
Each available presentation is listed separately. Current prices are confirmed from the Bear Biotech catalogue.
Available option
5mg
Lyophilised powder
Available option
10mg
Lyophilised powder
Available option
20mg
Lyophilised powder
Research overview
What is Retatrutide?
Retatrutide is a next-generation metabolic research peptide designed to activate GIP, GLP-1 and glucagon receptors in a single molecule. It has attracted major research attention because current late-stage clinical programmes are testing whether triple-receptor signalling produces a different metabolic profile from single- and dual-agonist approaches. Bear Biotech material is research-use-only and is not an approved retatrutide medicine.
Phase 2 human trials; phase 3 development; investigational
Research focus
Key research areas
Retatrutide research: one peptide, three receptor systems
Retatrutide is an investigational peptide designed to engage GIP, GLP-1 and glucagon receptors. Published trials concern defined investigational formulations, not generic catalogue material. Published findings concern defined experimental materials and do not establish the identity, quality, safety, efficacy or equivalence of Bear Biotech catalogue material.
- GIP receptor
- GLP-1 receptor
- Glucagon receptor
Representative primary research
Representative research
A randomised phase-2 trial investigated a regulated retatrutide product as a GIP, GLP-1 and glucagon receptor agonist.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial ↗ The trial product is not evidence of equivalence for catalogue research material.
These sources provide research context only. They do not verify the identity, quality or equivalence of a Bear Biotech catalogue batch; the matched lot-specific batch record remains controlling.
Specifications
Product information
- Material identity
- Retatrutide
- Research category
- Triple GIP/GLP-1/glucagon receptor agonist research material
- Evidence position
- Phase 2 human trials; phase 3 development; investigational
- Recorded formats
- Staff-prepared solution · Lyophilised powder
- Batch-record basis
- The matched lot-specific record controls identity and analytical claims.
- Intended use
- Controlled laboratory research only.
Research questions
Evidence and identity questions
What makes Retatrutide a triple-receptor agonist?
Retatrutide is investigated as a single molecule engaging GIP, GLP-1 and glucagon receptors. Interest centres on how three receptor systems interact within metabolic physiology.
Why must Retatrutide’s GLP-1, GIP and glucagon pathways be analysed together?
GLP-1-receptor activity is assessed alongside GIP- and glucagon-receptor signalling, so study design must separate individual pathway effects from the combined pharmacology.
What development stage defines the current Retatrutide evidence base?
Retatrutide has phase 2 human trial evidence and remains investigational while phase 3 development continues. A generic research material is not equivalent to a trial formulation.
Batch documentation
Lot-specific records stay connected to the order
Eligible lot-specific documentation may be viewed or requested from the registered Bear Biotech account when available for the applicable order.
Open Bear Biotech accountResearch use only
Controlled laboratory research material
Not for human or veterinary consumption. Administration, dosing and therapeutic guidance are not provided.